PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsEverolimus
Afinitor(everolimus)
Afinitor, Everolimus, Votubia, Zortress (everolimus) is a small molecule pharmaceutical. Everolimus was first approved as Afinitor on 2009-03-30. It has been approved in Europe to treat breast neoplasms, pancreatic neoplasms, renal cell carcinoma, and tuberous sclerosis. The pharmaceutical is active against serine/threonine-protein kinase mTOR.
Download report
Favorite
Novartis Pharmaceuticals
Drugs Approved for Childhood Cancers
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
nervous system diseasesD009422
urogenital diseasesD000091642
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
Trade Name
FDA
EMA
Afinitor, Afinitor disperz, Everolimus, Zortress (discontinued: Everolimus)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Everolimus
Tradename
Company
Number
Date
Products
AFINITORNovartisN-022334 RX2009-03-30
4 products, RLD
ZORTRESSNovartisN-021560 RX2010-04-20
4 products, RLD
AFINITOR DISPERZNovartisN-203985 RX2012-08-29
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
afinitorNew Drug Application2025-08-12
everolimusANDA2050-01-01
torpenzANDA2024-11-18
zortressNew Drug Application2025-08-12
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
EVEROLIMUS, AFINITOR DISPERZ, NOVARTIS PHARM
2025-04-10ODE-169
EVEROLIMUS, AFINITOR, NOVARTIS
2023-02-26ODE-108
Patent Expiration
Patent
Expires
Flag
FDA Information
Everolimus, Afinitor, Novartis
90062242028-07-01U-1681
84101312025-11-01U-1368
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EG: Mammalian target of rapamycin (mtor) kinase inhibitors
— L01EG02: Everolimus
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA18: Everolimus
HCPCS
Code
Description
J7527
Everolimus, oral, 0.25 mg
Clinical
Clinical Trials
1193 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324—I25.1122059136218
Breast neoplasmsD001943EFO_0003869C50387922316143
Myocardial ischemiaD017202EFO_1001375I20-I25—1102671108
NeoplasmsD009369—C8059363310102
Renal cell carcinomaD002292EFO_0000376—28501051396
Coronary diseaseD003327———19246094
CarcinomaD002277—C80.0225276684
Kidney transplantationD016030——391627558
Neuroendocrine tumorsD018358EFO_1001901D3A.8182493956
Coronary stenosisD023921EFO_1000882———4143149
Show 79 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney neoplasmsD007680EFO_0003865C648191—330
LymphomaD008223—C85.920171——30
Triple negative breast neoplasmsD064726——8163——24
Prostatic neoplasmsD011471—C619111—220
Stomach neoplasmsD013274EFO_0003897C16792——15
Carcinoid tumorD002276—D3A.00552——11
B-cell lymphomaD016393——561——10
LymphangioleiomyomatosisD018192—J84.81561—19
Large b-cell lymphoma diffuseD016403—C83.3551——9
Ovarian neoplasmsD010051EFO_0003893C56361——8
Show 33 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008——1612——227
Pancreatic neoplasmsD010190EFO_0003860C251014——221
LeukemiaD007938—C95169——119
Non-small-cell lung carcinomaD002289——164———18
Head and neck neoplasmsD006258——119———16
Colorectal neoplasmsD015179——712——115
Neuroendocrine carcinomaD018278——212——215
GlioblastomaD005909EFO_0000515—118———14
SarcomaD012509——38——313
GliomaD005910EFO_0000520—67———12
Show 157 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Merkel cell carcinomaD015266EFO_1001471C4A2————2
Medullary carcinomaD018276——2————2
Nasopharyngeal carcinomaD000077274——2————2
Laryngeal neoplasmsD007822EFO_0003817C322————2
Verrucous carcinomaD018289——2————2
Laryngeal diseasesD007818—J38.72————2
Uterine cervical neoplasmsD002583——2————2
Hematologic neoplasmsD019337——1————1
Myeloproliferative disordersD009196—D47.11————1
Myelomonocytic leukemia chronicD015477—C93.11————1
Show 35 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318EFO_0000319I98————1313
Arterial occlusive diseasesD001157EFO_0009085—————66
Drug-eluting stentsD054855——————33
Optical coherence tomographyD041623——————33
AngioplastyD017130——————22
HemorrhageD006470MP_0001914R58————22
Acute diseaseD000208——————11
Islets of langerhans transplantationD016381——————11
Mouth neoplasmsD009062EFO_0003868C06.9————11
NecrosisD009336——————11
Show 15 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEverolimus
INNeverolimus
Description
Everolimus is a macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent. It has a role as an antineoplastic agent, an immunosuppressive agent, a mTOR inhibitor, an anticoronaviral agent and a geroprotector. It is a primary alcohol, a secondary alcohol, an ether, a cyclic ketone, a cyclic acetal and a macrolide lactam. It is functionally related to a member of sirolimus.
Classification
Small molecule
Drug classimmunosuppressives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
Identifiers
PDB—
CAS-ID159351-69-6
RxCUI—
ChEMBL IDCHEMBL1908360
ChEBI ID68478
PubChem CID6442177
DrugBankDB01590
UNII ID9HW64Q8G6G (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Afinitor – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Zortress – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 42,345 documents
View more details
Safety
Black-box Warning
Black-box warning for: Everolimus, Zortress
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
55,543 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use